MarketCap
Facebook
X
TelegramAnnual report 2025
added 12-05-2025
The Cooper Companies Net Debt 2011-2026 | COO
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt The Cooper Companies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.38 B | 2.48 B | 2.44 B | 2.24 B | 1.34 B | 1.3 B | 1.67 B | 1.95 B | 1.08 B | 1.22 B | 1.33 B | 1.36 B | 267 M | 361 M | 375 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.48 B | 267 M | 1.45 B |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical instruments industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
-45 M | - | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
11.5 B | $ 19.97 | 1.17 % | $ 10.2 B | USA |
 |
Luminex Corporation
LMNX
|
-106 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
-517 K | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
-12.2 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
781 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
66.8 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
1.58 B | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
-411 M | - | -0.02 % | $ 16.3 B | USA |
 |
ICU Medical
ICUI
|
1.24 B | $ 148.98 | -0.7 % | $ 3.63 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-5.61 M | $ 8.86 | 5.6 % | $ 179 M | USA |
 |
Alcon
ALC
|
2.46 B | $ 81.1 | -0.04 % | $ 40.4 B |  Schweiz |
 |
AtriCure
ATRC
|
-59.2 M | $ 36.42 | -1.43 % | $ 1.71 B | USA |
 |
Repro Med Systems
KRMD
|
-10.8 M | $ 5.37 | -1.47 % | $ 245 M | USA |
 |
Haemonetics Corporation
HAE
|
623 M | $ 66.0 | 0.05 % | $ 3.32 B | USA |
 |
electroCore
ECOR
|
-9.7 M | $ 6.6 | -7.04 % | $ 36.4 K | USA |
 |
AngioDynamics
ANGO
|
-48.3 M | $ 10.3 | 3.16 % | $ 421 M | USA |
 |
InfuSystem Holdings
INFU
|
33.3 M | $ 8.16 | 1.49 % | $ 168 M | USA |
 |
Masimo Corporation
MASI
|
572 M | $ 134.6 | -1.21 % | $ 7.17 B | USA |
 |
Harvard Bioscience
HBIO
|
27.8 M | $ 0.5 | -6.45 % | $ 21.2 M | USA |
 |
Glaukos Corporation
GKOS
|
-21.6 M | $ 117.83 | -0.95 % | $ 5.71 B | USA |
 |
Merit Medical Systems
MMSI
|
363 M | $ 80.96 | 0.9 % | $ 4.71 B | USA |
 |
OraSure Technologies
OSUR
|
-266 M | $ 2.77 | -0.72 % | $ 206 M | USA |
 |
Isoray
ISR
|
-58.9 M | - | 0.03 % | $ 108 M | USA |
 |
iRhythm Technologies
IRTC
|
-329 M | $ 151.01 | 1.36 % | $ 4.71 B | USA |
 |
LeMaitre Vascular
LMAT
|
145 M | $ 84.27 | 0.48 % | $ 1.89 B | USA |
 |
Intuitive Surgical
ISRG
|
-1.88 B | $ 502.63 | -0.97 % | $ 179 B | USA |
 |
STERIS plc
STE
|
1.78 B | $ 260.46 | -0.53 % | $ 25.7 B | USA |
 |
NeuroMetrix
NURO
|
-1.49 M | - | 5.05 % | $ 9.02 M | USA |
 |
Microbot Medical
MBOT
|
-2.24 M | $ 1.83 | -1.61 % | $ 18.7 M |  Israel |
 |
Nephros
NEPH
|
-2.48 M | $ 4.45 | 1.37 % | $ 46.2 M | USA |
 |
Utah Medical Products
UTMD
|
-60.6 M | $ 60.82 | -1.35 % | $ 221 M | USA |
 |
Milestone Scientific
MLSS
|
-3.09 M | $ 0.29 | -2.9 % | $ 23.1 M | USA |
 |
Envista Holdings Corporation
NVST
|
244 M | $ 23.09 | -1.2 % | $ 3.98 B | USA |
 |
Pro-Dex
PDEX
|
15 M | $ 39.92 | 1.29 % | $ 131 M | USA |
 |
Predictive Oncology
POAI
|
1.4 M | - | - | $ 31.1 M | USA |
 |
Pulse Biosciences
PLSE
|
-35.2 M | $ 13.81 | 1.37 % | $ 663 M | USA |
 |
Becton, Dickinson and Company
BDX
|
17.1 B | $ 202.07 | 0.49 % | $ 58.1 B | USA |
 |
Repligen Corporation
RGEN
|
-236 M | $ 151.17 | -3.33 % | $ 8.42 M | USA |
 |
ResMed
RMD
|
513 M | $ 252.23 | -2.1 % | $ 36.8 B | USA |
 |
BioLife Solutions
BLFS
|
-88.9 M | $ 21.94 | -2.86 % | $ 1.01 B | USA |
 |
Stereotaxis
STXS
|
-14.3 M | $ 2.26 | -3.0 % | $ 182 M | USA |
 |
Retractable Technologies
RVP
|
-3 M | $ 0.7 | 1.3 % | $ 21 M | USA |
 |
STAAR Surgical Company
STAA
|
-105 M | $ 18.82 | -0.63 % | $ 925 M | USA |
 |
Teleflex Incorporated
TFX
|
1.37 B | $ 104.28 | -1.11 % | $ 4.88 B | USA |
 |
West Pharmaceutical Services
WST
|
-264 M | $ 228.14 | -1.87 % | $ 16.7 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.36 B | $ 12.36 | 0.73 % | $ 2.51 B | USA |